NeoGenomics, Inc.  

(Public, NASDAQ:NEO)   Watch this stock  
Find more results for Jennifer Murphy
-0.40 (-4.39%)
Jul 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 8.62 - 9.01
52 week 5.26 - 9.54
Open 9.00
Vol / Avg. 394,105.00/496,316.00
Mkt cap 673.20M
P/E     -
Div/yield     -
EPS -0.10
Shares 77.12M
Beta 1.33
Inst. own 73%
Oct 27, 2016
Q3 2016 Neogenomics Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jul 26, 2016
Q2 2016 Neogenomics Inc Earnings Call - Webcast
Jul 26, 2016
Q2 2016 Neogenomics Inc Earnings Release
Jun 14, 2016
Neogenomics Inc at William Blair Growth Stock Conference
Jun 10, 2016
Neogenomics Inc Annual Shareholders Meeting (Estimated)
Jun 7, 2016
Neogenomics Inc Annual Shareholders Meeting
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin 0.26% -2.54%
Operating margin 3.22% -5.65%
EBITD margin - 1.51%
Return on average assets 0.18% -1.17%
Return on average equity -10.45% -1.97%
Employees 850 -
CDP Score - -


12701 Commonwealth Dr Ste 9
FORT MYERS, FL 33913-8626
United States - Map
+1-941-9231949 (Phone)
+1-775-3290852 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


NeoGenomics, Inc. is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. Its Laboratory Testing segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. The Company offers testing services, which includes Cytogenetics testing, which is the study of normal and abnormal chromosomes and their relationship to disease; fluorescence in-situ hybridization (FISH) testing, which is a branch of cancer genetics that focuses on detecting and locating the presence or absence of specific deoxyribonucleic acid (DNA) sequences and genes on chromosomes; flow cytometry testing, which is a way to measure the characteristics of cell populations, and immunohistochemistry (IHC), and digital imaging, which is a process of localizing proteins in cells of a tissue section and relies on the principle of antibodies binding specifically to antigens in biological tissues.

Officers and directors

Douglas M. VanOort Chairman of the Board, Chief Executive Officer
Age: 59
Bio & Compensation  - Reuters
George A. Cardoza Chief Financial Officer
Age: 53
Bio & Compensation  - Reuters
Edwin F. Weidig III, CPA Director - Finance , Principal Accounting Officer
Age: 45
Bio & Compensation  - Reuters
Robert J. Shovlin Chief Operating Officer
Age: 44
Bio & Compensation  - Reuters
Steven C. Jones Executive Vice President - Finance, Chief Compliance Officer, Director
Age: 52
Bio & Compensation  - Reuters
Steven A. Ross Chief Information Officer
Age: 51
Bio & Compensation  - Reuters
Steven G. Brodie Phd. Chief Scientific Officer
Age: 54
Bio & Compensation  - Reuters
Mark Machulcz Vice President - Operations
Age: 52
Bio & Compensation  - Reuters
Jennifer Balliet Vice President - Human Resources
Age: 38
Bio & Compensation  - Reuters
Sally Agersborg M.D. Ph.D. Director of Hematopathology and Medical Director
Bio & Compensation  - Reuters